## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

212477Orig1s000

## **OFFICER/EMPLOYEE LIST**



MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE

FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

DATE:

August 26, 2019

TO:

Administrative file for NDA 212477

FROM:

Philip Villasurda, PharmD, Regulatory Health Project Manager

Division of Antiviral Products, Office of Antimicrobial Products

SUBJECT:

Officer/Employee List for NDA 212477

APPLICATION/DRUG:

NDA 212477, HARVONI®, ledipasvir/sofosbuvir, oral pellets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Birnkrant, Debra B

Chikhale, Elsbeth G

Choi, Su-Young

Davis, Nathan

Dorantes, Angelica

El-Kamary, Samer

Englund, Erika

Ghantous, Hanan

Griffiths, LaShawn

Harris, Sarah

Hassan, Hazem

Johnson, Anitra

Kolejian, Sevan

Lewis, David B

Li, Ruojing

Li, Zheng

Lunn, George

Min, Stacey

Mishra, Lalji

Murray, Jeffrey S

O'Rear, Julian

Ou, Mei

Soldatova, Lyudmila

Strayhorn, Suzanne



Struble, Kimberly Swank, Kimberley Walker, Morgan Wilson, Valerie

